Infection Risk With Biologic Therapy in Patients With Inflammatory Bowel Disease.
Fiche publication
Date publication
octobre 2017
Journal
Clinical pharmacology and therapeutics
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Hindryckx P, Novak G, Bonovas S, Peyrin-Biroulet L, Danese S
Lien Pubmed
Résumé
The development of biologic drugs revolutionized the management of inflammatory bowel diseases: Crohn's disease and ulcerative colitis. However, while their efficacy has been well established, it remains uncertain to what extent biologic treatments may be associated with important safety risks, such as serious infections, opportunistic infections, or tuberculosis reactivation. Herein, we review and discuss the current evidence on the infection risk associated with biologic therapy in patients with inflammatory bowel disease (IBD).
Mots clés
Biological Therapy, adverse effects, Humans, Immunologic Factors, adverse effects, Infection, epidemiology, Inflammatory Bowel Diseases, drug therapy, Opportunistic Infections, epidemiology, Tuberculosis, epidemiology
Référence
Clin. Pharmacol. Ther.. 2017 Oct;102(4):633-641